Pfizer (NYSE: PFE) shares are up 13% in pre-open Friday after the company presented testing data of its COVID-19 oral ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Corporate News FDA Hot Comments Hot Corp. News Hot FDA News

Merck (MRK) and Ridgeback Announce Additional Purchase of 1.4M Courses of Molnupiravir by the US GovernmentNovember 9, 2021 6:04 AM Merck (MRK) Acquisition of Acceleron Pharma Cleared by Antitrust Authorities in Germany and AustriaNovember 8, 2021 4:32 PM Merck (MRK) ahead of Pfizer (PFE) in EU talks on COVID-19 pills -EU source - ReutersNovember 8, 2021 11:15 AM Pfizer's (PFE) COVID Pill Best in Class, Will Put Pressure on Merck (MRK) and Regeneron (REGN) - AnalystNovember 5, 2021 8:47 AM Mizuho Defends Merck (MRK) on Weakness Related to Pfizer's Antiviral DrugNovember 5, 2021 8:32 AM Airlines, Reopening Stocks Surge Following Data From Pfizer (PFE) Antiviral Covid PillNovember 5, 2021 7:25 AM Pfizer says its antiviral pill slashes risk of severe COVID-19 by 89%November 5, 2021 6:59 AM Pfizer (PFE) PT Raised to $44 at Mizuho SecuritiesNovember 4, 2021 6:36 AM Pfizer (PFE) PT Raised to $46 at Wolfe ResearchNovember 3, 2021 6:04 AM Pfizer (PFE) PT Raised to $44 at BarclaysNovember 3, 2021 4:35 AM